Premium
Pharmacokinetics of antipyrine in epileptic patients.
Author(s) -
Rimmer EM,
Routledge PA,
Tsanaclis LM,
Richens A
Publication year - 1986
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1986.tb02833.x
Subject(s) - pharmacokinetics , bioavailability , oral administration , pharmacology , medicine , half life , liver enzyme , drug , enzyme inducer , drug metabolism , first pass effect , enzyme , chemistry , biochemistry
The pharmacokinetics of antipyrine were examined after oral and intravenous administration to 20 epileptic subjects receiving antiepileptic drug therapy. Bioavailability was essentially complete (mean bioavailability 101.2% +/‐ 14.4 (s.d.] indicating that even in enzyme induced subjects, antipyrine behaves as a restrictively eliminated compound with negligible presystemic elimination in the gut or liver. Of the generally used measures of enzyme induction (oral clearance, oral half‐life and intravenous half‐life) oral clearance was the most closely related to the intravenous clearance of antipyrine (r = 0.919, P less than 0.001). Oral antipyrine administration is an alternative to intravenous administration in epileptic subjects who are enzyme‐induced.